RxDoctor Payments Data

Jeffrey Sanders, MD

Urology · Waco, TXNPI 1790898146

Payments from drug & device makers

$968in general payments, 2019–2025

Across 36 payments — averaging $26.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$385
  • Johnson & Johnson$175
  • Boston Scientific$107
  • Telix Pharmaceuticals$105
  • Antares Pharma, Inc.$40
  • Pfizer$34
  • plus $122 from 5 others

What the payments were for

  • Food & beverage$93196%
  • Education$364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc11$385
Johnson & Johnson(2 entities)11$175
Boston Scientific2$107
Telix Pharmaceuticals1$105
Antares Pharma, Inc.2$40
Pfizer2$34
AbbVie(2 entities)2$33
Blue Earth Diagnostics2$28
Bayer1$23
Metuchen Pharmaceuticals1$23
AMAG Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$968 in reported general payments places this provider in the 20th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$290,802
Medicare patients
736
Services billed
4,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron33$25,419
Tamsulosin Hcl502$8,099
Mirabegron ErMirabegron12$6,476
ErtapenemErtapenem Sodium12$6,147
Solifenacin Succinate212$6,133
Cephalexin516$5,907
Trospium Chloride92$5,041
Testosterone Cypionate83$4,326
Finasteride291$3,980
Estradiol39$3,627
Potassium Citrate ErPotassium Citrate39$3,550
Trospium Chloride ErTrospium Chloride19$1,980
Gemcitabine Hcl38$1,565
Alfuzosin Hcl ErAlfuzosin Hcl60$1,299
Imipramine Hcl41$1,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$385$25,41933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 878 urology providers in Texas.

Other urology in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →